Paper of the Month September 2023
Importance of Blood Glucose Management before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin
This section highlights recently published scientific articles relevant to nuclear medicine practice and research. Selected papers provide concise insights into emerging evidence, clinical applications, and methodological developments to support continuous professional learning.
Importance of Blood Glucose Management before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin
Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
18-F-FDG PET maximum intensity projections and articicial intelligence : A win-win to easily measure prognostic biomarkers in DLBCL patients.
Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis demonstrated by [177Lu]Lu-PSMA
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG-PET in patients with metastatic non-small cell lung cancer.
Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on 18F-FDG PET/CT: A Focus in Breast Cancer Care
68Ga-DOTA Positron Emission Tomography for Diagnosis of Spinal Cerebrospinal Fluid Leaks prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial
[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial
Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication
Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
The Added Value of Bloodpool SPECT/CT in Painful Non-Operated Foot and Ankle Undiagnosed With Standard Three-Phase Bone Scintigraphy
Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell
Scientists want virtual meetings to stay after the COVID pandemic
Diagnosing Transthyretin Cardiac Amyloidosis by Technetium 99m Pyrophosphate: A Test in Evolution. Poterucha TJ, et al. JACC Cardiovasc Imaging. 2020:S1936-878X(20)30816-0.
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F] FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Incremental diagnosic value of 18 [F]tetrafluoroborate PET-CT compared to 131[I]iodine scintigraphy in recurrent differentiated thyroid cancer
Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging Schmidkonz C, Rauber S, Atzinger A, et al. Ann Rheum Dis Published Online First: 21 July 2020
FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patientsEur J Nucl Med Mol Imaging. 2020 Apr 27 : 1–8.
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy- A Systematic Review This paper, from the Mayo Clinic Cancer Center, presents the results of a systematic literature review of the incidence of therapy-related myeloid neoplasm (t-MNN) as a potential long-term and frequently lethal adverse event after PRRT. 7334 patients treated with […]
COVID19 – Nuclear Medicine Departments, be prepared! Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/31707430 Journal: https://journals.lww.com/nuclearmedicinecomm/fulltext/2020/04000/covid19__nuclear_medicine_departments,_be.1.aspx
Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/31707430 Journal: https://link.springer.com/article/10.1007%2Fs00259-019-04567-2
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers – Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med. 2019 Jul 19;8(7). pii: E1060.
Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden J Nucl Med. 2019 Aug;60(8):1096-1102
Reference: «Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism»
Discussion: By selecting this paper, I would like to stress once again the importance of prospective studies in the development and in vivo evaluation of potential new tracers and their corresponding drug registration. Especially in the field of PSMA tracers, there is still a lot of work to be done here. As early as 2004, […]
Title: Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy Isabel Rauscher1, Markus Krönke1, Michael König1, Andrei Gafita1, Tobias Maurer2,3, Thomas Horn2, Kilian Schiller4, Wolfgang Weber1, Matthias Eiber1 J Nucl Med. 2019 Jun 28. Weblinks to article: Pubmed JNM Discussion This exploratory matched-pair study mainly […]
This month: FAPI-PET/CT: Mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer. First experience with a new F18-labeled PET tracer for cancer imaging, called FAPI PET/CT developed by the Heidelberg group. The same group (Uwe haberkorn) was also at the basis of the succesful development of the Ga68 and F18-labeled PSMA-ligands for prostate […]
This month: A Preliminary Study of Ankle Single Photon Emission Computed Tomography/Computed Tomography in Patients With Bony Impingement Syndrome: Association With the Visual Analogue Scale Pain Score. Both osteoarthritis and impingement syndrome are commonly observed in sports and orthopedic medicine. Ankle impingement is a painful mechanical limitation of full ankle movement secondary to osseous/soft-tissue abnormality and […]
This month: [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study 177Lu-PSMA-617 therapy is being implemented in clinical routine for treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) in several countries. Simultaneously, Endocyte is running its large VISION-trail, which is an international, prospective, open Label, multicenter, randomized phase […]
This month: Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT Enjoy the reading, your BELNUC Board Journal link
This month: 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Enjoy the reading, your BELNUC Board Journal link
This month: Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European Survey Enjoy the reading, your BELNUC Board Pubmed link Journal link
This month we feature a LANCET Oncology paper published online on October 8, 2018, evaluating the prognostic value of metabolic response assessed by PET and morphologic response assessed by CT after first-line immunochemotherapy in a large population of patients with follicular lymphoma. Enjoy the reading, the BELNUC Board « Prognostic value of end-of-induction PET response after […]